Nasus Pharma Ltd has announced the departure of its Interim Chief Financial Officer, Oren Elmaliah, effective November 11, 2026. This change is significant as it may influence the company's financial strategies and investor relations moving forward.
Background
Nasus Pharma Ltd is a company listed on the NYSE under the ticker NSRX. It operates within the pharmaceutical preparations industry, classified under SIC code 2834. The company is incorporated in L3 and has a fiscal year ending on December 31.
What the Filing Says
The recent filing states, "This Exit Form 4 has been filed solely to report that Reporting Person ceased to serve as the Interim Chief Financial Officer of Nasus Pharma Ltd..." This indicates that Elmaliah is no longer subject to the reporting obligations under Section 16 of the Securities Exchange Act of 1934.
Impact
Elmaliah's departure may affect various stakeholders, including investors and employees, as the company seeks to fill the financial leadership role. The transition could lead to changes in financial oversight and strategic direction.
What's Next
The filing does not say what happens next.
Reporting Obligations
As noted in the filing, Oren Elmaliah is no longer subject to the reporting obligations under Section 16 of the Securities Exchange Act of 1934. This change signifies a shift in the company's regulatory landscape, as Elmaliah's departure from the role of Interim Chief Financial Officer may impact how the company reports its financial activities and governance.
Company Information
Nasus Pharma Ltd is incorporated in L3 and operates from its business address located at 29 Harakevet St, Tel Aviv - Yafo, L3, 6618003, Israel. The company is classified under the SIC code 2834, which pertains to pharmaceutical preparations, indicating its focus on the development and commercialization of pharmaceutical products.
Filing Details
The Form 4 filing was submitted with an acceptance date of November 16, 2026, and it reports the cessation of Elmaliah's role effective November 11, 2026. The filing is categorized under SEC Act 1934 and includes the company's Central Index Key (CIK) number 0002029039.
Future Leadership
The filing does not provide any details regarding who will succeed Elmaliah as Interim Chief Financial Officer or any interim measures the company may take during this transition period.
Read Next
Nancy Killefer Acquires 755 Shares of Cardinal Health Inc.
Cheniere Energy Partners Appoints Zach Davis as President
Musslewhite acquires shares in Cardinal Health transaction
Dury Michael R. Reports Significant Stock Transaction
Aptiv CFO Laroyia Varun Acquires 14,702 Shares
Murray Jason W. reports stock transaction for Sysco Corp







